# A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

> **NCT05726292** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 90 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Relacorilant
- **DRUG:** Enzalutamide
- **OTHER:** Placebo (Sugar Pill)
- **OTHER:** Androgen Deprivation Therapy
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT05726292
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726292, "A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05726292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*